Funds report 834,752 Lantern Pharma (LTRN) shares in ownership update

Rhea-AI Filing Summary

Lantern Pharma Inc. received an updated ownership report from a group of Bios and Cavu investment entities in Amendment No. 6 to a beneficial ownership filing. The group, including Bios Equity Partners, Bios Equity Partners II, Cavu Management, Cavu Advisors and related funds, reports aggregate beneficial ownership of 834,752 shares of common stock, equal to 7.4% of the outstanding shares.

Their shared voting and dispositive power is held through several limited partnerships such as Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT. Percentages are calculated using 11,254,697 shares outstanding as reported in Lantern Pharma’s Form 10‑Q filed on March 16, 2026.

Key Figures

Group beneficial ownership: 834,752 shares Group ownership percentage: 7.4% of class Bios Equity Partners stake: 420,802 shares +4 more

7 metrics

Group beneficial ownership 834,752 shares Aggregate Lantern Pharma common shares reported by several Bios and Cavu entities

Group ownership percentage 7.4% of class Beneficial ownership of Lantern Pharma common stock by the reporting group

Bios Equity Partners stake 420,802 shares Lantern Pharma shares with shared voting and dispositive power via Bios Equity Partners, LP

Bios Equity Partners percentage 3.7% of class Ownership of Lantern Pharma common stock attributed to Bios Equity Partners, LP

Bios Equity Partners II stake 413,950 shares Lantern Pharma shares with shared voting and dispositive power via Bios Equity Partners II, LP

Bios Equity Partners II percentage 3.7% of class Ownership of Lantern Pharma common stock attributed to Bios Equity Partners II, LP

Lantern Pharma shares outstanding 11,254,697 shares Outstanding common shares as reported in Lantern Pharma’s Form 10-Q on March 16, 2026

Key Terms

beneficially owned, shared voting power, shared dispositive power, percent of class, +2 more

6 terms

beneficially owned financial

"Number of Shares Beneficially Owned by Each Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 834,752.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 834,752.00"

percent of class financial

"Percent of class represented by amount in Row (11) 7.4 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

general partner financial

"Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT."

A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.

Schedule 13D regulatory

"This Amendment No. 6 hereby amends and supplements the statement on originally filed"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Lantern Pharma Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

51654W101

(CUSIP Number)

Bios Equity Partners, LP
1751 River Run, Suite 400
Fort Worth, TX, 76107
817-984-9197

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/16/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Bios Equity Partners, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 420,802.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 420,802.00

11

Aggregate amount beneficially owned by each reporting person

420,802.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Fletcher Aaron G.L.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 834,752.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 834,752.00

11

Aggregate amount beneficially owned by each reporting person

834,752.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Advisors GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 834,752.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 834,752.00

11

Aggregate amount beneficially owned by each reporting person

834,752.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Capital Management, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 834,752.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 834,752.00

11

Aggregate amount beneficially owned by each reporting person

834,752.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Bios Equity Partners II, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 413,950.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 413,950.00

11

Aggregate amount beneficially owned by each reporting person

413,950.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 88,029 Shares directly held by Bios Fund II, (ii) 287,442 Shares directly held by Bios Fund II QP and (iii) 38,479 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Fund II, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 88,029.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 88,029.00

11

Aggregate amount beneficially owned by each reporting person

88,029.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Fund II NT, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 38,479.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 38,479.00

11

Aggregate amount beneficially owned by each reporting person

38,479.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Fund II QP, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 287,442.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 287,442.00

11

Aggregate amount beneficially owned by each reporting person

287,442.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.6 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Fund I, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 249,037.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 249,037.00

11

Aggregate amount beneficially owned by each reporting person

249,037.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.2 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS Fund I QP, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 145,672.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 145,672.00

11

Aggregate amount beneficially owned by each reporting person

145,672.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BP Directors, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 26,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 26,093.00

11

Aggregate amount beneficially owned by each reporting person

26,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Cavu Advisors, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 834,752.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 834,752.00

11

Aggregate amount beneficially owned by each reporting person

834,752.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Cavu Management, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 834,752.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 834,752.00

11

Aggregate amount beneficially owned by each reporting person

834,752.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Kreis Leslie W.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 834,752.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 834,752.00

11

Aggregate amount beneficially owned by each reporting person

834,752.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Lantern Pharma Inc.
(c)	Address of Issuer's Principal Executive Offices: 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS, TEXAS , 75201.
Item 1 Comment: This Amendment No. 6 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statements on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), March 1, 2024 ("Amendment No. 3"), June 12, 2025 ("Amendment No. 4"), February 23, 2026 ("Amendment No. 5"), and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer").
Item 5.	Interest in Securities of the Issuer
(a)	The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.
(b)	The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.
(d)	Except as described in this Amendment No. 6, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D.
(e)	Not applicable
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bios Equity Partners, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

Fletcher Aaron G.L.

Signature:	/s/ John Fucci
Name/Title:	John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher
Date:	04/16/2026

BIOS Advisors GP, LLC

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BIOS Capital Management, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

Bios Equity Partners II, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BIOS Fund II, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BIOS Fund II NT, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BIOS Fund II QP, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BIOS Fund I, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BIOS Fund I QP, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

BP Directors, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

Cavu Advisors, LLC

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

Cavu Management, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	04/16/2026

Kreis Leslie W.

Signature:	/s/ John Fucci
Name/Title:	John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr.
Date:	04/16/2026

Comments accompanying signature:

BIOS FUND II, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II QP, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II NT, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorneyin-Fact BIOS INCYSUS CO-INVEST I, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III NT, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS CLINICAL OPPORTUNITY FUND, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner BP DIRECTORS, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS II, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in Fact BIOS EQUITY PARTNERS III, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS EQUITY COF, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner CAVU MANAGEMENT, LP By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci Attorney-in-Fact BIOS CAPITAL MANAGEMENT, LP By: Bios Advisors GP, LLC its general partner By: /s/ John Fucci Attorney in-Fact

FAQ

What level of ownership in Lantern Pharma (LTRN) do the Bios and Cavu entities report?

The Bios and Cavu entities report beneficial ownership of 834,752 shares of Lantern Pharma common stock, representing 7.4% of the outstanding shares. This ownership is held through multiple affiliated investment funds and management entities acting together.

Which investment funds hold Lantern Pharma (LTRN) shares in this Schedule 13D/A?

Reported holders include Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT. These funds collectively contribute to the group’s 834,752 Lantern Pharma shares with shared voting and dispositive power across the entities.

How is the 7.4% Lantern Pharma (LTRN) ownership percentage calculated?

The 7.4% beneficial ownership figure is based on 11,254,697 Lantern Pharma shares outstanding, as reported in the company’s Form 10‑Q filed on March 16, 2026. The group’s 834,752 shares is measured against that outstanding share count.

What stake does Bios Equity Partners hold in Lantern Pharma (LTRN)?

Bios Equity Partners reports beneficial ownership of 420,802 Lantern Pharma shares, representing 3.7% of the common stock. These shares are held through Bios Fund I, Bios Fund I QP and BP Directors, over which Bios Equity Partners has shared voting and dispositive power.

Who are the individuals associated with the reported Lantern Pharma (LTRN) holdings?

Individuals named include Aaron G.L. Fletcher and Leslie W. Kreis, each reporting shared beneficial ownership of 834,752 shares, or 7.4% of Lantern Pharma’s stock, through control relationships with Bios and Cavu general partner and management entities.